Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Röshammar D, Simonsson US, Ekvall H, Flamholc L, Ormaasen V, Vesterbacka J, Wallmark E, Ashton M, Gisslén M. Röshammar D, et al. Among authors: vesterbacka j. J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):727-42. doi: 10.1007/s10928-011-9217-1. Epub 2011 Oct 2. J Pharmacokinet Pharmacodyn. 2011. PMID: 21964996 Clinical Trial.
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
Andersson LM, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, Sönnerborg A, Gisslén M. Andersson LM, et al. Among authors: vesterbacka j. Scand J Infect Dis. 2013 Jul;45(7):543-51. doi: 10.3109/00365548.2012.756985. Epub 2013 Jan 7. Scand J Infect Dis. 2013. PMID: 23294034 Clinical Trial.
Gut microbiota diversity predicts immune status in HIV-1 infection.
Nowak P, Troseid M, Avershina E, Barqasho B, Neogi U, Holm K, Hov JR, Noyan K, Vesterbacka J, Svärd J, Rudi K, Sönnerborg A. Nowak P, et al. Among authors: vesterbacka j. AIDS. 2015 Nov 28;29(18):2409-18. doi: 10.1097/QAD.0000000000000869. AIDS. 2015. PMID: 26355675
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page